NT-503 ECT

 

The Phase 2 clinical study of a soluble anti vascular endothelial growth factor (anti-VEGF) receptor protein (NT-503) delivered by Encapsulated Cell Therapy (ECT) in the treatment of wet AMD has been discontinued. The study was stopped due to a larger than anticipated number of patients requiring rescue medication in the treatment arm. ECT was well tolerated for the duration of the trial and there was no observed safety signal that contributed to the decision to discontinue the trial.

 

Although we have decided to terminate this trial, Neurotech is deeply committed to the ECT platform. We firmly believe in the technology and its ability to produce single or combination therapeutic proteins for sustained periods of time.

 

Neurotech © 2016

News Update

Find out the latest news at Neurotech